The 20 references in paper A. Stupnitskaya Ya., А. Ступницкая Я. (2014) “ЭФФЕКТИВНОСТЬ ИСПОЛЬЗОВАНИЯ АТОРВАСТАТИНА В КОМБИНАЦИИ С АМЛОДИПИНОМ У БОЛЬНЫХ ХРОНИЧЕСКОЙОБСТРУКТИВНОЙ БОЛЕЗНЬЮ ЛЕГКИХ С СОПУТСТВУЮЩИМ МЕТАБОЛИЧЕСКИМ СИНДРОМОМ // EFFICACY OF ATORVASTATIN PLUS AMLODIPINE COMBINATION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND COMORBID METABOLIC SYNDROME” / spz:neicon:pulmonology:y:2014:i:1:p:43-47

1
Fabbri L.M., Luppi F., Beghe B., Rabe K.F. et al. Complex chronic comorbidities of COPD Eur. Respir. J. 2008; 31 (1):
(check this in PDF content)
2
4–212. 2.Barnes P.J., Celli B.R.Systemic manifestations and comorbidities of COPD. Eur. Respir. J. 2009; 33: 1165–1185.
(check this in PDF content)
3
Magnussen H., Watz Н. Systemic inflammation in COPD and asthma: relation with comorbidities. Proc. Am. Thorac. Soc. 2009; 6: 648–651.
(check this in PDF content)
4
Poulain M., Doucet M., Drapeau V. et al. Metabolic and inflammatory profile in obese patients with chronic obstructive pulmonary disease. Chron. Respir. Dis. 2008; 5 (1): 35–41.
(check this in PDF content)
5
Skyba P., Ukropec J., Pobeha P. et al. Metabolic phenotype and adipose tissue inflammation in patients with chronic obstructive pulmonary disease. Mediat. Inflamm. 2010; 2010: 173498.
(check this in PDF content)
6
Tkacova R.Systemic inflammation in chronic obstructive pulmonary disease: may adipose tissue play a role? Review of the literature and future perspectives. Mediat. Inflamm. 2010; 2010: 585989–586000.
(check this in PDF content)
7
Clini E., Crisafulli E., Radaeli A., Malerba M. COPD and the metabolic syndrome: an intriguing association. Intern. Emerg. Med. 2013; 8 (4): 283–289.
(check this in PDF content)
8
Watz H., Waschki B., Kirsten A. et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest 2009; 136: 1039–1046.
(check this in PDF content)
9
Kupeli E., Ulubay G., Ulasli S.S. et al.Metabolic syndrome is associated with increased risk of acute exacerbation of COPD: a preliminary study. Endocrine 2010; 38 (1): 76–82.
(check this in PDF content)
10
Patel A.R.C., Hurst S.R.Extrapulmonary comorbidities in chronic obstructive pulmonary disease: stat of the art. Expert Rev. Respir. Med. 2011; 5: 647–662. Таблица 3 Динамика показателей при терапии комбинацией амлодипина и аторвастатина у больных ХОБЛ + МС ПоказательИсходный уровень (n = 15)Уровень после курса лечения (n= 15)∆, %р Масса тела, кг94,97 ± 5,1887,06 ± 3,98–8,3< 0,05 Содержание жира в организме, %28,69 ± 2,0025,75 ± 1,86–10,2< 0,05 ИМТ32,43 ± 1,3128,88 ± 1,12–10,9< 0,001 САД, мм рт. ст.146,43 ± 3,29131,43 ± 2,59–10,50,001 ДАД, мм рт. ст.90,36 ± 1,4381,43 ± 1,33–9,9< 0,05 6-МШТ314,67 ± 10,94356,60 ± 11,3911,80,001 ТГ, ммоль / л2,69 ± 0,212,07 ± 0,18–23,1< 0,05 ХС ЛПНП, ед.60,86 ± 3,1452,29 ± 1,66–14,1< 0,05 ХС ЛПОНП, ммоль / л1,22 ± 0,090,77 ± 0,07–3
(check this in PDF content)
11
Chatila W.M., Thomashow B.M., Minai O.A. et al.Comorbidities in COPD. Proc. Am. Thorac. Soc. 2008; 5: 449–553.
(check this in PDF content)
12
Dobler C.C., Wong K.K., Marks G.B. Associations between statins and COPD: a systematic review. BMC Pulm. Med. 2009; 9: 32.
(check this in PDF content)
13
Janda S., Park K., Gerald M.F. Statins in COPD. Chest 2009; 136: 734–743.
(check this in PDF content)
14
Young R.P., Hopkins R., Eaton T.E.Pharmacological actions of statins: potential utility in COPD. Eur. Respir. Rev. 2009; 18: 222–232.
(check this in PDF content)
15
Cowan D.C., Cowan J.O., Palmay R. et al. Simvastatin in the treatment of asthma: lack of steroid-sparing effect. Thorax 2010; 65: 891–896.
(check this in PDF content)
16
Mortensen E.M., Copeland L.A., Pugh M.J.V. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir. Res. 2009; 10: 45.
(check this in PDF content)
17
Lawes C.M.M., Thornley S., Young R. et al. Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Prim. Care Respir. J. 2012; 21: 35–40.
(check this in PDF content)
18
Mancini G.B., Etminan M., Zhang B. et al.Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J. Am. Coll. Cardiol. 2006; 47: 2554–2560.
(check this in PDF content)
19
Wells C.E., Baker E.H.Metabolic syndrome and diabetes mellitus in COPD. Eur. Respir. Monogr. 2013; 59: 117–134.
(check this in PDF content)
20
Young R.P., Hopkins R., Eaton T.E.Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. Postgrad. Med. J. 2009; 85: 414–421. Информация об авторе
(check this in PDF content)